Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031
The Human Microbiome market is expected to reach USD 7.09 billion in 2031 from USD 1.40 billion in 2024, at a CAGR of 31.0% during the forecast period. Factors such as the collaborative efforts between the microbiome industry and academia for microbiome research and the growing demand for personalized medicine are driving the growth of the human microbiome market. However, complex regulatory policies adversely impact the commercialization of microbiomes, restraining market growth.
The probiotics segment accounted for the largest share of the human microbiome supplements segment in 2024.
The market is segmented into human microbiome drugs, human microbiome supplements, and human microbiome diagnostics. The human microbiome supplements are analyzed across three key products: probiotics, prebiotics, and synbiotics. The segment with the biggest share in the human microbiome market in 2024 is probiotics. This dominance is attributed to their widespread use, strong consumer awareness, and established presence in over-the-counter health and wellness products. Probiotics are commonly used to support digestive health, boost immunity, and maintain gut microbial balance, making them a routine part of preventive healthcare. They are available in various formats, including capsules, powders, beverages, and functional foods, enhancing accessibility and consumer adoption. Additionally, a large body of clinical research supports the efficacy of specific probiotic strains, reinforcing trust among consumers and healthcare providers. The ability to pair probiotics with other bioactives like prebiotics or vitamins has further expanded their appeal across various demographics. Collectively, these factors have made probiotics the leading product type in the human microbiome supplements segment.
In 2024, the gastrointestinal diseases segment accounted for the largest share of the market.
The human microbiome market is segmented into gastrointestinal diseases, infectious diseases, endocrine & metabolic disorders, and other diseases. In 2024, the gastrointestinal diseases segment accounted for the largest share of the market. This is driven by the strong association between gut microbiota and conditions such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), ulcerative colitis, and Crohn’s disease. These chronic disorders have a high global prevalence and often require long-term management, creating demand for alternative and adjunctive therapies that target the gut microbiome.
A growing body of research supports the role of microbial imbalances in the development and progression of gastrointestinal conditions, prompting increased investment in microbiome-based diagnostics and treatments. Several clinical-stage products targeting IBD and IBS are in development, reflecting scientific interest and unmet patient needs. The availability of microbiome supplements aimed at digestive health, such as probiotics and synbiotics, has further expanded consumer access and contributed to market growth in this segment.
In 2024, North America accounted for the largest share of the human microbiome market.
North America accounted for the largest share of the human microbiome market in 2024. This is due to several factors, including a strong presence of key market players, advanced healthcare infrastructure, and high levels of investment in microbiome research and development. The region hosts numerous clinical trials and academic collaborations focused on microbiome science, particularly in the United States. Regulatory support has also contributed to market growth, with the US FDA approving the first microbiome-based therapeutics, such as VOWST and Rebyota, setting important regulatory precedents. In addition, North America has a large and growing consumer base for microbiome supplements, particularly probiotics and synbiotics, driven by rising awareness of gut health and preventive wellness. High healthcare spending, increasing prevalence of chronic diseases, and favorable reimbursement policies further reinforce the leading position of North America in the global human microbiome market.
The primary interviews conducted for this report can be categorized as follows:
Research Coverage
This research report categorizes the Human Microbiome market by Product (Human Microbiome Drugs, Human Microbiome Supplements [Probiotics, Prebiotics, Synbiotics], Human Microbiome Diagnostics), Disease (Infectious disease, Gastrointestinal Disease, Endocrine, and metabolic disorders, Cancer, and Other Diseases), Drugs & Supplements Type (Bacterial Consortia Transplantation (BCT)/ Fecal Microbiota Transplantation (FMT), Peptides, Live Bacteria Products, and Others), Drugs & Supplements Route of Administration (Oral, Rectal), End User (Hospitals & Clinics, Long-term care Facilities, Other End Users), Manufacturing Service (Strain Development & Optimization, Fermentation & Downstream Processing, Formulation & Fill/Finish, Other Services) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the Human Microbiome market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the Human Microbiome market. Competitive analysis of top players and upcoming startups in the human microbiome market ecosystem is covered in this report.
The scope of the report covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the human microbiome market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the human microbiome market. This report covers the competitive analysis of upcoming startups in the human microbiome market ecosystem.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Human Microbiome market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Collaborative initiatives between organizations, academia, and the microbiome industry, Increase in the number of Startups,/SMEs exploring the microbiome niche, Advancements in microbiome sequencing), restraints (Adverse impact of complex regulatory policies on commercialization of microbiomes, High investment in commercialization of microbiome drugs), opportunities (Increase in demand for personalized medicine, and Emergence of synbiotics), and challenges (Slow patient adoption of microbiome-based therapies and Complexities involved in development of microbiome therapies) influencing the growth of the market.
The probiotics segment accounted for the largest share of the human microbiome supplements segment in 2024.
The market is segmented into human microbiome drugs, human microbiome supplements, and human microbiome diagnostics. The human microbiome supplements are analyzed across three key products: probiotics, prebiotics, and synbiotics. The segment with the biggest share in the human microbiome market in 2024 is probiotics. This dominance is attributed to their widespread use, strong consumer awareness, and established presence in over-the-counter health and wellness products. Probiotics are commonly used to support digestive health, boost immunity, and maintain gut microbial balance, making them a routine part of preventive healthcare. They are available in various formats, including capsules, powders, beverages, and functional foods, enhancing accessibility and consumer adoption. Additionally, a large body of clinical research supports the efficacy of specific probiotic strains, reinforcing trust among consumers and healthcare providers. The ability to pair probiotics with other bioactives like prebiotics or vitamins has further expanded their appeal across various demographics. Collectively, these factors have made probiotics the leading product type in the human microbiome supplements segment.
In 2024, the gastrointestinal diseases segment accounted for the largest share of the market.
The human microbiome market is segmented into gastrointestinal diseases, infectious diseases, endocrine & metabolic disorders, and other diseases. In 2024, the gastrointestinal diseases segment accounted for the largest share of the market. This is driven by the strong association between gut microbiota and conditions such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), ulcerative colitis, and Crohn’s disease. These chronic disorders have a high global prevalence and often require long-term management, creating demand for alternative and adjunctive therapies that target the gut microbiome.
A growing body of research supports the role of microbial imbalances in the development and progression of gastrointestinal conditions, prompting increased investment in microbiome-based diagnostics and treatments. Several clinical-stage products targeting IBD and IBS are in development, reflecting scientific interest and unmet patient needs. The availability of microbiome supplements aimed at digestive health, such as probiotics and synbiotics, has further expanded consumer access and contributed to market growth in this segment.
In 2024, North America accounted for the largest share of the human microbiome market.
North America accounted for the largest share of the human microbiome market in 2024. This is due to several factors, including a strong presence of key market players, advanced healthcare infrastructure, and high levels of investment in microbiome research and development. The region hosts numerous clinical trials and academic collaborations focused on microbiome science, particularly in the United States. Regulatory support has also contributed to market growth, with the US FDA approving the first microbiome-based therapeutics, such as VOWST and Rebyota, setting important regulatory precedents. In addition, North America has a large and growing consumer base for microbiome supplements, particularly probiotics and synbiotics, driven by rising awareness of gut health and preventive wellness. High healthcare spending, increasing prevalence of chronic diseases, and favorable reimbursement policies further reinforce the leading position of North America in the global human microbiome market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
- By Designation: C-level Executives - 55%, Directors- 20%, and Others- 25%
- By Region: North America -45%, Europe - 20%, Asia Pacific -20%, Latin America -10%, the Middle East- 3%, and Africa-2%
Research Coverage
This research report categorizes the Human Microbiome market by Product (Human Microbiome Drugs, Human Microbiome Supplements [Probiotics, Prebiotics, Synbiotics], Human Microbiome Diagnostics), Disease (Infectious disease, Gastrointestinal Disease, Endocrine, and metabolic disorders, Cancer, and Other Diseases), Drugs & Supplements Type (Bacterial Consortia Transplantation (BCT)/ Fecal Microbiota Transplantation (FMT), Peptides, Live Bacteria Products, and Others), Drugs & Supplements Route of Administration (Oral, Rectal), End User (Hospitals & Clinics, Long-term care Facilities, Other End Users), Manufacturing Service (Strain Development & Optimization, Fermentation & Downstream Processing, Formulation & Fill/Finish, Other Services) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the Human Microbiome market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the Human Microbiome market. Competitive analysis of top players and upcoming startups in the human microbiome market ecosystem is covered in this report.
The scope of the report covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the human microbiome market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the human microbiome market. This report covers the competitive analysis of upcoming startups in the human microbiome market ecosystem.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Human Microbiome market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Collaborative initiatives between organizations, academia, and the microbiome industry, Increase in the number of Startups,/SMEs exploring the microbiome niche, Advancements in microbiome sequencing), restraints (Adverse impact of complex regulatory policies on commercialization of microbiomes, High investment in commercialization of microbiome drugs), opportunities (Increase in demand for personalized medicine, and Emergence of synbiotics), and challenges (Slow patient adoption of microbiome-based therapies and Complexities involved in development of microbiome therapies) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the human microbiome market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the Human Microbiome market Competitive Assessment: Seres Therapeutics (US), Ferring B.V. (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc. (US), Pendulum (US), Biohm Technologies (US), Actial Farmaceutica Srl (Italy), OptiBiotix Health Plc (UK), resbiotic (US), Infinant Health Inc (US), BioGaia (Sweden), ExeGi Pharma (US), Finch Therapeutics Group, Inc. (US), Infant Bacterial Therapeutics AB (Sweden), MaaT Pharma (France), Microba (Australia), Viome Life Sciences, Inc. (US), and Genova Diagnostics (US) among others in the market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
2.3 GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 HUMAN MICROBIOME MARKET OVERVIEW
4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE AND COUNTRY, 2024
4.3 HUMAN MICROBIOME MARKET, BY TYPE, 2025 VS. 2031
4.4 HUMAN MICROBIOME MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.5 HUMAN MICROBIOME MARKET, BY END USER, 2025
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Collaborative initiatives between organizations and academia
5.2.1.2 Increasing number of startups/SMEs exploring microbiome
5.2.1.3 Advancements in microbiome sequencing
5.2.2 RESTRAINTS
5.2.2.1 Complex regulatory policies
5.2.2.2 High investments in commercializing microbiome drugs
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing demand for personalized medicines
5.2.3.2 Emergence of postbiotics
5.2.4 CHALLENGES
5.2.4.1 Slow patient adoption of microbiome-based therapies
5.2.4.2 Complexities in developing microbiome therapies
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.3.1 DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY
5.3.1.1 Market readiness
5.3.1.2 Adoption
5.3.1.3 Maturity
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024
5.4.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2022–2024
5.5 VALUE CHAIN ANALYSIS
5.5.1 HUMAN MICROBIOME DRUGS
5.5.2 HUMAN MICROBIOME SUPPLEMENTS
5.5.3 HUMAN MICROBIOME DIAGNOSTICS
5.6 ECOSYSTEM ANALYSIS
5.6.1 ECOSYSTEM SHIFT
5.6.1.1 Specialized raw material and data suppliers
5.6.1.2 Hot-bet innovator startups
5.6.1.3 Integrated end users and prosumer models
5.6.1.4 Regulatory and quality assurance orchestrators
5.6.1.5 Diagnostics-driven personalization
5.6.1.6 Microbiome-as-a-Service (Maas)
5.6.2 EMERGING BUSINESS MODELS
5.6.2.1 Emerging B2C model
5.6.2.2 Personalized supplements model
5.6.3 INTERCONNECTED MARKET DYNAMICS
5.7 INVESTMENT AND FUNDING SCENARIO
5.7.1 MAJOR INVESTMENTS AND FUNDING BY KEY MARKET PLAYERS
5.7.2 OTHER INVESTMENTS AND FUNDING
5.8 TECHNOLOGY ANALYSIS
5.8.1 KEY TECHNOLOGIES
5.8.1.1 Whole-genome sequencing
5.8.1.2 16s RNA sequencing method
5.8.1.3 Nanopore sequencing
5.8.2 COMPLEMENTARY TECHNOLOGIES
5.8.2.1 Metatranscriptomics
5.8.2.2 Metagenomics
5.8.2.3 Metabolomics
5.8.3 ADJACENT TECHNOLOGIES
5.8.3.1 Sample preparation
5.8.3.2 Data analysis
5.8.3.3 Library synthesis
5.9 PATENT ANALYSIS
5.10 KEY CONFERENCES AND EVENTS, 2025–2026
5.11 CASE STUDY ANALYSIS
5.11.1 EFFECT OF REBYOTA ON QUALITY OF LIFE IN PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
5.11.2 ECOSPOR IV STUDY OF VOWST FOR CLOSTRIDIOIDES DIFFICILE INFECTION
5.11.3 DELONG#3 STUDY FOR QUALITY OF LIFE IMPROVEMENT BY VSL#3 PROBIOTIC IN POST-COVID-19 PATIENTS
5.12 TARIFF AND REGULATORY ANALYSIS
5.12.1 TARIFF DATA (HS CODE 3002.90)
5.12.2 REGULATORY LANDSCAPE
5.12.2.1 North America
5.12.2.1.1 US
5.12.2.1.2 Canada
5.12.2.2 Europe
5.12.2.2.1 UK
5.12.2.3 Asia Pacific
5.12.2.3.1 China
5.12.2.3.2 Japan
5.12.2.3.3 South Korea
5.12.2.3.4 Australia
5.12.2.3.5 Rest of Asia Pacific
5.12.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 BARGAINING POWER OF SUPPLIERS
5.13.2 BARGAINING POWER OF BUYERS
5.13.3 THREAT OF NEW ENTRANTS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 PIPELINE ANALYSIS
5.16 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET
5.16.1 INTRODUCTION
5.16.2 MARKET POTENTIAL OF AI IN HUMAN MICROBIOME MARKET
5.16.3 AI USE CASES
5.16.4 KEY PLAYERS IMPLEMENTING AI
5.16.5 FUTURE OF GENERATIVE AI IN HUMAN MICROBIOME MARKET
5.17 IMPACT OF US TARIFF ON HUMAN MICROBIOME MARKET
5.17.1 KEY TARIFF RATES
5.17.2 PRICE IMPACT ANALYSIS
5.17.3 KEY IMPACT ON COUNTRY/REGION
5.17.3.1 US
5.17.3.2 Europe
5.17.3.3 Asia Pacific
5.17.3.4 Rest of the World
5.17.4 IMPACT ON END-USE INDUSTRY
5.17.4.1 Hospitals and clinics
5.17.4.2 Long-term care facilities
5.18 MANAGING GLP-1 SIDE EFFECTS WITH MICROBIOME INTERVENTIONS
5.19 FUTURE TRENDS IN HUMAN MICROBIOME MARKET
5.19.1 TYPE
5.19.2 DISEASE
5.19.3 END USER
6 HUMAN MICROBIOME MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 DRUGS
6.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS IN LATE-STAGE CLINICAL TRIALS TO DRIVE MARKET
6.3 SUPPLEMENTS
6.3.1 PROBIOTICS
6.3.1.1 Increasing consumer awareness about probiotics for improved gut health and immunity to aid growth
6.3.2 PREBIOTICS
6.3.2.1 Rising development of targeted prebiotics to expedite growth
6.3.3 SYNBIOTICS
6.3.3.1 Growing demand for personalized treatment and rising incidence of dysbiosis to fuel market
6.4 DIAGNOSTICS
6.4.1 INCREASING PRODUCT LAUNCHES AND TECHNOLOGY TRANSFER TO FACILITATE GROWTH
7 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT)
7.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT GROWTH
7.3 LIVE BACTERIA PRODUCTS (LBP)
7.3.1 INCREASING CONSUMER FOCUS ON PREVENTIVE HEALTH TO AID GROWTH
7.4 OTHER MICROBIOME TYPES
8 HUMAN MICROBIOME MARKET, BY DISEASE
8.1 INTRODUCTION
8.2 INFECTIOUS DISEASES
8.2.1 EMERGENCE OF MULTIDRUG-RESISTANT BACTERIA TO FOSTER GROWTH
8.3 GASTROINTESTINAL DISEASES
8.3.1 INCREASING DEMAND FOR PERSONALIZED THERAPIES TO AID GROWTH
8.4 ENDOCRINE & METABOLIC DISORDERS
8.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR METABOLIC DISORDERS TO BOOST MARKET
8.5 OTHER DISEASES
9 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION
9.1 INTRODUCTION
9.2 ORAL ROUTE OF ADMINISTRATION
9.2.1 WIDESPREAD PATIENT ACCEPTANCE AND EXTENSIVE PRODUCT OFFERINGS TO ENCOURAGE GROWTH
9.3 RECTAL ROUTE OF ADMINISTRATION
9.3.1 ABILITY TO RESTORE HEALTHY GUT TO FACILITATE GROWTH
10 HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE
10.1 INTRODUCTION
10.2 STRAIN DEVELOPMENT & OPTIMIZATION
10.2.1 RISING DEMAND FOR TARGETED, STRAIN-SPECIFIC MICROBIOME THERAPIES TO BOOST MARKET
10.3 FERMENTATION & DOWNSTREAM PROCESSING
10.3.1 GROWING DEMAND FOR CLINICAL-STAGE BIOTHERAPEUTICS TO DRIVE MARKET
10.4 FORMULATION & FILL/FINISH
10.4.1 INCREASING STUDIES ON LIVE BIOTHERAPEUTIC PRODUCTS TO PROMOTE GROWTH
10.5 OTHER SERVICES
11 HUMAN MICROBIOME MARKET, BY END USER
11.1 INTRODUCTION
11.2 HOSPITALS & CLINICS
11.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT GROWTH
11.3 LONG-TERM CARE FACILITIES
11.3.1 NEED FOR SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET
11.4 OTHER END USERS
12 HUMAN MICROBIOME MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 Favorable government initiatives and booming diagnostics sector to drive market
12.2.3 CANADA
12.2.3.1 Increasing prevalence of chronic diseases to expedite growth
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 Rapid increase in government and private funding to propel market
12.3.3 UK
12.3.3.1 Significant government investments in microbiome research and presence of microbiome companies to propel growth
12.3.4 FRANCE
12.3.4.1 Growing focus on developing new products and services using microbiome data to boost market
12.3.5 ITALY
12.3.5.1 Rise in research activities to encourage growth
12.3.6 SPAIN
12.3.6.1 Favorable microbiome research landscape to support growth
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Rapidly expanding healthcare industry to accelerate growth
12.4.3 JAPAN
12.4.3.1 Booming geriatric population to contribute to growth
12.4.4 INDIA
12.4.4.1 Increasing number of human microbiome diagnostic companies to augment growth
12.4.5 SOUTH KOREA
12.4.5.1 Booming bio-health market to advance growth
12.4.6 AUSTRALIA
12.4.6.1 Growing number of product approvals to boost markt
12.4.7 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Rising probiotics demand to drive market
12.5.3 REST OF LATIN AMERICA
12.6 MIDDLE EAST
12.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST
12.6.2 GCC COUNTRIES
12.6.2.1 Saudi Arabia
12.6.2.1.1 Growing focus on healthcare infrastructure to fuel market
12.6.2.2 UAE
12.6.2.2.1 Increasing focus on immunotherapy and biotechnology to augment growth
12.6.2.3 Rest of GCC countries
12.6.3 REST OF MIDDLE EAST
12.7 AFRICA
12.7.1 INCREASING STUDIES AND INITIATIVES ON MICROBIOME TO PROMOTE GROWTH
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET
13.3 REVENUE ANALYSIS, 2022–2024
13.4 MARKET SHARE ANALYSIS, 2024
13.5 COMPANY VALUATION AND FINANCIAL METRICS
13.6 BRAND/PRODUCT COMPARISON
13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.4 PARTICIPANTS
13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
13.7.5.1 Company footprint
13.7.5.2 Region footprint
13.7.5.3 Product footprint
13.7.5.4 Type footprint
13.7.5.5 Disease footprint
13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
13.8.1 PROGRESSIVE COMPANIES
13.8.2 RESPONSIVE COMPANIES
13.8.3 DYNAMIC COMPANIES
13.8.4 STARTING BLOCKS
13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
13.8.5.1 Detailed list of key startups/SMEs
13.8.5.2 Competitive benchmarking of key emerging players/startups
13.9 COMPETITIVE SCENARIO
13.9.1 PRODUCT LAUNCHES AND APPROVALS
13.9.2 DEALS
13.9.3 EXPANSIONS
14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 INTERNATIONAL FLAVORS & FRAGRANCES INC.
14.1.1.1 Business overview
14.1.1.2 Products offered
14.1.1.3 Recent developments
14.1.1.3.1 Deals
14.1.1.3.2 Expansions
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses and competitive threats
14.1.2 SEED HEALTH, INC.
14.1.2.1 Business overview
14.1.2.2 Products offered
14.1.2.3 Recent developments
14.1.2.3.1 Product launches and approvals
14.1.2.3.2 Deals
14.1.2.3.3 Expansions
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 SERES THERAPEUTICS
14.1.3.1 Business overview
14.1.3.2 Products offered
14.1.3.3 Recent developments
14.1.3.3.1 Product launches and approvals
14.1.3.3.2 Deals
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses and competitive threats
14.1.4 FERRING B.V.
14.1.4.1 Business overview
14.1.4.2 Products offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches and approvals
14.1.4.3.2 Deals
14.1.4.4 MnM view
14.1.4.4.1 Key strengths
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses and competitive threats
14.1.5 PENDULUM
14.1.5.1 Business overview
14.1.5.2 Products offered
14.1.5.3 Recent developments
14.1.5.3.1 Product launches and approvals
14.1.5.3.2 Deals
14.1.5.4 MnM view
14.1.5.4.1 Key strengths
14.1.5.4.2 Strategic choices
14.1.5.4.3 Weaknesses and competitive threats
14.1.6 OPTIBIOTIX HEALTH PLC
14.1.6.1 Business overview
14.1.6.2 Products offered
14.1.6.3 Recent developments
14.1.6.3.1 Product launches and approvals
14.1.6.3.2 Deals
14.1.7 BIOGAIA
14.1.7.1 Business overview
14.1.7.2 Products offered
14.1.7.3 Recent developments
14.1.7.3.1 Product launches and approvals
14.1.7.3.2 Deals
14.1.7.3.3 Expansions
14.1.8 MAAT PHARMA
14.1.8.1 Business overview
14.1.8.2 Products offered
14.1.8.3 Recent developments
14.1.8.3.1 Deals
14.1.8.3.2 Other developments
14.1.9 MICROBA
14.1.9.1 Business overview
14.1.9.2 Products offered
14.1.9.3 Recent developments
14.1.9.3.1 Product launches and approvals
14.1.10 BIOMEBANK
14.1.10.1 Business overview
14.1.10.2 Products offered
14.1.10.3 Recent developments
14.1.10.3.1 Product launches and approvals
14.1.10.3.2 Deals
14.1.10.3.3 Expansions
14.1.11 BIOHM HEALTH
14.1.11.1 Business overview
14.1.11.2 Products offered
14.1.11.3 Recent developments
14.1.11.3.1 Deals
14.1.12 ACTIAL FARMACEUTICA SRL
14.1.12.1 Business overview
14.1.12.2 Products offered
14.1.13 RESBIOTIC
14.1.13.1 Business overview
14.1.13.2 Products offered
14.1.13.3 Recent developments
14.1.13.3.1 Product launches and approvals
14.1.13.3.2 Deals
14.1.13.3.3 Expansions
14.1.14 INFINANT HEALTH INC.
14.1.14.1 Business overview
14.1.14.2 Products offered
14.1.14.3 Recent developments
14.1.14.3.1 Deals
14.1.15 EXEGI PHARMA
14.1.15.1 Business overview
14.1.15.2 Products offered
14.1.15.3 Recent developments
14.1.15.3.1 Deals
14.1.16 FINCH THERAPEUTICS GROUP, INC.
14.1.16.1 Business overview
14.1.16.2 Products offered
14.1.16.3 Recent developments
14.1.16.3.1 Deals
14.1.17 INFANT BACTERIAL THERAPEUTICS AB
14.1.17.1 Business overview
14.1.17.2 Products offered
14.1.18 VIOME LIFESCIENCES
14.1.18.1 Business overview
14.1.18.2 Products offered
14.1.18.3 Recent developments
14.1.18.3.1 Product launches and approvals
14.1.19 GENOVA DIAGNOSTICS
14.1.19.1 Business overview
14.1.19.2 Products offered
14.2 OTHER PLAYERS
14.2.1 AOBIOME
14.2.2 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.
14.2.3 NUBIYOTA
14.2.4 OXTHERA
14.2.5 NEXBIOME
14.2.6 VEDANTA BIOSCIENCES, INC.
14.2.7 ENTEROME
14.2.8 APSEN FARMACEUTICA
14.2.9 METAGEN, INC.
14.2.10 SNIPR BIOME
14.2.11 MIKROBIOMIK
14.2.12 SYNLOGIC
14.2.13 GENETIC ANALYSIS
14.2.14 METABIOMICS
14.2.15 SUN GENOMICS, INC.
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
2.3 GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 HUMAN MICROBIOME MARKET OVERVIEW
4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE AND COUNTRY, 2024
4.3 HUMAN MICROBIOME MARKET, BY TYPE, 2025 VS. 2031
4.4 HUMAN MICROBIOME MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.5 HUMAN MICROBIOME MARKET, BY END USER, 2025
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Collaborative initiatives between organizations and academia
5.2.1.2 Increasing number of startups/SMEs exploring microbiome
5.2.1.3 Advancements in microbiome sequencing
5.2.2 RESTRAINTS
5.2.2.1 Complex regulatory policies
5.2.2.2 High investments in commercializing microbiome drugs
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing demand for personalized medicines
5.2.3.2 Emergence of postbiotics
5.2.4 CHALLENGES
5.2.4.1 Slow patient adoption of microbiome-based therapies
5.2.4.2 Complexities in developing microbiome therapies
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.3.1 DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY
5.3.1.1 Market readiness
5.3.1.2 Adoption
5.3.1.3 Maturity
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024
5.4.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2022–2024
5.5 VALUE CHAIN ANALYSIS
5.5.1 HUMAN MICROBIOME DRUGS
5.5.2 HUMAN MICROBIOME SUPPLEMENTS
5.5.3 HUMAN MICROBIOME DIAGNOSTICS
5.6 ECOSYSTEM ANALYSIS
5.6.1 ECOSYSTEM SHIFT
5.6.1.1 Specialized raw material and data suppliers
5.6.1.2 Hot-bet innovator startups
5.6.1.3 Integrated end users and prosumer models
5.6.1.4 Regulatory and quality assurance orchestrators
5.6.1.5 Diagnostics-driven personalization
5.6.1.6 Microbiome-as-a-Service (Maas)
5.6.2 EMERGING BUSINESS MODELS
5.6.2.1 Emerging B2C model
5.6.2.2 Personalized supplements model
5.6.3 INTERCONNECTED MARKET DYNAMICS
5.7 INVESTMENT AND FUNDING SCENARIO
5.7.1 MAJOR INVESTMENTS AND FUNDING BY KEY MARKET PLAYERS
5.7.2 OTHER INVESTMENTS AND FUNDING
5.8 TECHNOLOGY ANALYSIS
5.8.1 KEY TECHNOLOGIES
5.8.1.1 Whole-genome sequencing
5.8.1.2 16s RNA sequencing method
5.8.1.3 Nanopore sequencing
5.8.2 COMPLEMENTARY TECHNOLOGIES
5.8.2.1 Metatranscriptomics
5.8.2.2 Metagenomics
5.8.2.3 Metabolomics
5.8.3 ADJACENT TECHNOLOGIES
5.8.3.1 Sample preparation
5.8.3.2 Data analysis
5.8.3.3 Library synthesis
5.9 PATENT ANALYSIS
5.10 KEY CONFERENCES AND EVENTS, 2025–2026
5.11 CASE STUDY ANALYSIS
5.11.1 EFFECT OF REBYOTA ON QUALITY OF LIFE IN PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
5.11.2 ECOSPOR IV STUDY OF VOWST FOR CLOSTRIDIOIDES DIFFICILE INFECTION
5.11.3 DELONG#3 STUDY FOR QUALITY OF LIFE IMPROVEMENT BY VSL#3 PROBIOTIC IN POST-COVID-19 PATIENTS
5.12 TARIFF AND REGULATORY ANALYSIS
5.12.1 TARIFF DATA (HS CODE 3002.90)
5.12.2 REGULATORY LANDSCAPE
5.12.2.1 North America
5.12.2.1.1 US
5.12.2.1.2 Canada
5.12.2.2 Europe
5.12.2.2.1 UK
5.12.2.3 Asia Pacific
5.12.2.3.1 China
5.12.2.3.2 Japan
5.12.2.3.3 South Korea
5.12.2.3.4 Australia
5.12.2.3.5 Rest of Asia Pacific
5.12.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 BARGAINING POWER OF SUPPLIERS
5.13.2 BARGAINING POWER OF BUYERS
5.13.3 THREAT OF NEW ENTRANTS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 PIPELINE ANALYSIS
5.16 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET
5.16.1 INTRODUCTION
5.16.2 MARKET POTENTIAL OF AI IN HUMAN MICROBIOME MARKET
5.16.3 AI USE CASES
5.16.4 KEY PLAYERS IMPLEMENTING AI
5.16.5 FUTURE OF GENERATIVE AI IN HUMAN MICROBIOME MARKET
5.17 IMPACT OF US TARIFF ON HUMAN MICROBIOME MARKET
5.17.1 KEY TARIFF RATES
5.17.2 PRICE IMPACT ANALYSIS
5.17.3 KEY IMPACT ON COUNTRY/REGION
5.17.3.1 US
5.17.3.2 Europe
5.17.3.3 Asia Pacific
5.17.3.4 Rest of the World
5.17.4 IMPACT ON END-USE INDUSTRY
5.17.4.1 Hospitals and clinics
5.17.4.2 Long-term care facilities
5.18 MANAGING GLP-1 SIDE EFFECTS WITH MICROBIOME INTERVENTIONS
5.19 FUTURE TRENDS IN HUMAN MICROBIOME MARKET
5.19.1 TYPE
5.19.2 DISEASE
5.19.3 END USER
6 HUMAN MICROBIOME MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 DRUGS
6.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS IN LATE-STAGE CLINICAL TRIALS TO DRIVE MARKET
6.3 SUPPLEMENTS
6.3.1 PROBIOTICS
6.3.1.1 Increasing consumer awareness about probiotics for improved gut health and immunity to aid growth
6.3.2 PREBIOTICS
6.3.2.1 Rising development of targeted prebiotics to expedite growth
6.3.3 SYNBIOTICS
6.3.3.1 Growing demand for personalized treatment and rising incidence of dysbiosis to fuel market
6.4 DIAGNOSTICS
6.4.1 INCREASING PRODUCT LAUNCHES AND TECHNOLOGY TRANSFER TO FACILITATE GROWTH
7 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT)
7.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT GROWTH
7.3 LIVE BACTERIA PRODUCTS (LBP)
7.3.1 INCREASING CONSUMER FOCUS ON PREVENTIVE HEALTH TO AID GROWTH
7.4 OTHER MICROBIOME TYPES
8 HUMAN MICROBIOME MARKET, BY DISEASE
8.1 INTRODUCTION
8.2 INFECTIOUS DISEASES
8.2.1 EMERGENCE OF MULTIDRUG-RESISTANT BACTERIA TO FOSTER GROWTH
8.3 GASTROINTESTINAL DISEASES
8.3.1 INCREASING DEMAND FOR PERSONALIZED THERAPIES TO AID GROWTH
8.4 ENDOCRINE & METABOLIC DISORDERS
8.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR METABOLIC DISORDERS TO BOOST MARKET
8.5 OTHER DISEASES
9 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION
9.1 INTRODUCTION
9.2 ORAL ROUTE OF ADMINISTRATION
9.2.1 WIDESPREAD PATIENT ACCEPTANCE AND EXTENSIVE PRODUCT OFFERINGS TO ENCOURAGE GROWTH
9.3 RECTAL ROUTE OF ADMINISTRATION
9.3.1 ABILITY TO RESTORE HEALTHY GUT TO FACILITATE GROWTH
10 HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE
10.1 INTRODUCTION
10.2 STRAIN DEVELOPMENT & OPTIMIZATION
10.2.1 RISING DEMAND FOR TARGETED, STRAIN-SPECIFIC MICROBIOME THERAPIES TO BOOST MARKET
10.3 FERMENTATION & DOWNSTREAM PROCESSING
10.3.1 GROWING DEMAND FOR CLINICAL-STAGE BIOTHERAPEUTICS TO DRIVE MARKET
10.4 FORMULATION & FILL/FINISH
10.4.1 INCREASING STUDIES ON LIVE BIOTHERAPEUTIC PRODUCTS TO PROMOTE GROWTH
10.5 OTHER SERVICES
11 HUMAN MICROBIOME MARKET, BY END USER
11.1 INTRODUCTION
11.2 HOSPITALS & CLINICS
11.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT GROWTH
11.3 LONG-TERM CARE FACILITIES
11.3.1 NEED FOR SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET
11.4 OTHER END USERS
12 HUMAN MICROBIOME MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 Favorable government initiatives and booming diagnostics sector to drive market
12.2.3 CANADA
12.2.3.1 Increasing prevalence of chronic diseases to expedite growth
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 Rapid increase in government and private funding to propel market
12.3.3 UK
12.3.3.1 Significant government investments in microbiome research and presence of microbiome companies to propel growth
12.3.4 FRANCE
12.3.4.1 Growing focus on developing new products and services using microbiome data to boost market
12.3.5 ITALY
12.3.5.1 Rise in research activities to encourage growth
12.3.6 SPAIN
12.3.6.1 Favorable microbiome research landscape to support growth
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Rapidly expanding healthcare industry to accelerate growth
12.4.3 JAPAN
12.4.3.1 Booming geriatric population to contribute to growth
12.4.4 INDIA
12.4.4.1 Increasing number of human microbiome diagnostic companies to augment growth
12.4.5 SOUTH KOREA
12.4.5.1 Booming bio-health market to advance growth
12.4.6 AUSTRALIA
12.4.6.1 Growing number of product approvals to boost markt
12.4.7 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Rising probiotics demand to drive market
12.5.3 REST OF LATIN AMERICA
12.6 MIDDLE EAST
12.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST
12.6.2 GCC COUNTRIES
12.6.2.1 Saudi Arabia
12.6.2.1.1 Growing focus on healthcare infrastructure to fuel market
12.6.2.2 UAE
12.6.2.2.1 Increasing focus on immunotherapy and biotechnology to augment growth
12.6.2.3 Rest of GCC countries
12.6.3 REST OF MIDDLE EAST
12.7 AFRICA
12.7.1 INCREASING STUDIES AND INITIATIVES ON MICROBIOME TO PROMOTE GROWTH
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET
13.3 REVENUE ANALYSIS, 2022–2024
13.4 MARKET SHARE ANALYSIS, 2024
13.5 COMPANY VALUATION AND FINANCIAL METRICS
13.6 BRAND/PRODUCT COMPARISON
13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.4 PARTICIPANTS
13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
13.7.5.1 Company footprint
13.7.5.2 Region footprint
13.7.5.3 Product footprint
13.7.5.4 Type footprint
13.7.5.5 Disease footprint
13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
13.8.1 PROGRESSIVE COMPANIES
13.8.2 RESPONSIVE COMPANIES
13.8.3 DYNAMIC COMPANIES
13.8.4 STARTING BLOCKS
13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
13.8.5.1 Detailed list of key startups/SMEs
13.8.5.2 Competitive benchmarking of key emerging players/startups
13.9 COMPETITIVE SCENARIO
13.9.1 PRODUCT LAUNCHES AND APPROVALS
13.9.2 DEALS
13.9.3 EXPANSIONS
14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 INTERNATIONAL FLAVORS & FRAGRANCES INC.
14.1.1.1 Business overview
14.1.1.2 Products offered
14.1.1.3 Recent developments
14.1.1.3.1 Deals
14.1.1.3.2 Expansions
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses and competitive threats
14.1.2 SEED HEALTH, INC.
14.1.2.1 Business overview
14.1.2.2 Products offered
14.1.2.3 Recent developments
14.1.2.3.1 Product launches and approvals
14.1.2.3.2 Deals
14.1.2.3.3 Expansions
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 SERES THERAPEUTICS
14.1.3.1 Business overview
14.1.3.2 Products offered
14.1.3.3 Recent developments
14.1.3.3.1 Product launches and approvals
14.1.3.3.2 Deals
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses and competitive threats
14.1.4 FERRING B.V.
14.1.4.1 Business overview
14.1.4.2 Products offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches and approvals
14.1.4.3.2 Deals
14.1.4.4 MnM view
14.1.4.4.1 Key strengths
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses and competitive threats
14.1.5 PENDULUM
14.1.5.1 Business overview
14.1.5.2 Products offered
14.1.5.3 Recent developments
14.1.5.3.1 Product launches and approvals
14.1.5.3.2 Deals
14.1.5.4 MnM view
14.1.5.4.1 Key strengths
14.1.5.4.2 Strategic choices
14.1.5.4.3 Weaknesses and competitive threats
14.1.6 OPTIBIOTIX HEALTH PLC
14.1.6.1 Business overview
14.1.6.2 Products offered
14.1.6.3 Recent developments
14.1.6.3.1 Product launches and approvals
14.1.6.3.2 Deals
14.1.7 BIOGAIA
14.1.7.1 Business overview
14.1.7.2 Products offered
14.1.7.3 Recent developments
14.1.7.3.1 Product launches and approvals
14.1.7.3.2 Deals
14.1.7.3.3 Expansions
14.1.8 MAAT PHARMA
14.1.8.1 Business overview
14.1.8.2 Products offered
14.1.8.3 Recent developments
14.1.8.3.1 Deals
14.1.8.3.2 Other developments
14.1.9 MICROBA
14.1.9.1 Business overview
14.1.9.2 Products offered
14.1.9.3 Recent developments
14.1.9.3.1 Product launches and approvals
14.1.10 BIOMEBANK
14.1.10.1 Business overview
14.1.10.2 Products offered
14.1.10.3 Recent developments
14.1.10.3.1 Product launches and approvals
14.1.10.3.2 Deals
14.1.10.3.3 Expansions
14.1.11 BIOHM HEALTH
14.1.11.1 Business overview
14.1.11.2 Products offered
14.1.11.3 Recent developments
14.1.11.3.1 Deals
14.1.12 ACTIAL FARMACEUTICA SRL
14.1.12.1 Business overview
14.1.12.2 Products offered
14.1.13 RESBIOTIC
14.1.13.1 Business overview
14.1.13.2 Products offered
14.1.13.3 Recent developments
14.1.13.3.1 Product launches and approvals
14.1.13.3.2 Deals
14.1.13.3.3 Expansions
14.1.14 INFINANT HEALTH INC.
14.1.14.1 Business overview
14.1.14.2 Products offered
14.1.14.3 Recent developments
14.1.14.3.1 Deals
14.1.15 EXEGI PHARMA
14.1.15.1 Business overview
14.1.15.2 Products offered
14.1.15.3 Recent developments
14.1.15.3.1 Deals
14.1.16 FINCH THERAPEUTICS GROUP, INC.
14.1.16.1 Business overview
14.1.16.2 Products offered
14.1.16.3 Recent developments
14.1.16.3.1 Deals
14.1.17 INFANT BACTERIAL THERAPEUTICS AB
14.1.17.1 Business overview
14.1.17.2 Products offered
14.1.18 VIOME LIFESCIENCES
14.1.18.1 Business overview
14.1.18.2 Products offered
14.1.18.3 Recent developments
14.1.18.3.1 Product launches and approvals
14.1.19 GENOVA DIAGNOSTICS
14.1.19.1 Business overview
14.1.19.2 Products offered
14.2 OTHER PLAYERS
14.2.1 AOBIOME
14.2.2 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.
14.2.3 NUBIYOTA
14.2.4 OXTHERA
14.2.5 NEXBIOME
14.2.6 VEDANTA BIOSCIENCES, INC.
14.2.7 ENTEROME
14.2.8 APSEN FARMACEUTICA
14.2.9 METAGEN, INC.
14.2.10 SNIPR BIOME
14.2.11 MIKROBIOMIK
14.2.12 SYNLOGIC
14.2.13 GENETIC ANALYSIS
14.2.14 METABIOMICS
14.2.15 SUN GENOMICS, INC.
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 HUMAN MICROBIOME MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
TABLE 3 HUMAN MICROBIOME MARKET: RISK ANALYSIS
TABLE 4 HUMAN MICROBIOME MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 5 INDUSTRY COLLABORATIONS IN HUMAN MICROBIOME MARKET, 2022–2024
TABLE 6 LIST OF STARTUPS/SMES IN HUMAN MICROBIOME MARKET
TABLE 7 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)
TABLE 8 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2022–2024 (USD)
TABLE 9 HUMAN MICROBIOME MARKET: MAJOR INVESTMENT AND FUNDING, 2022–2024
TABLE 10 HUMAN MICROBIOME MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023–2024
TABLE 11 HUMAN MICROBIOME MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
TABLE 12 TARIFF DATA FOR HS CODE 3002.90
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 REGULATORY LANDSCAPE OF LIVE BIOTHERAPEUTIC PRODUCTS
TABLE 18 HUMAN MICROBIOME MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
TABLE 20 KEY BUYING CRITERIA, BY END USER
TABLE 21 KEY PLAYERS IMPLEMENTING AI IN HUMAN MICROBIOME
TABLE 22 COMPANIES LEVERAGING AI IN HUMAN MICROBIOME MARKET
TABLE 23 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 24 KEY PRODUCT-RELATED TARIFF: PHARMACEUTICAL PRODUCTS, MISCELLANEOUS EDIBLE PREPARATIONS, AND PRODUCTS OF ANIMAL ORIGIN
TABLE 25 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES
TABLE 26 HUMAN MICROBIOME SUPPLEMENTS POSITIONED AS GLP-1 SUPPORT
TABLE 27 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 28 HUMAN MICROBIOME DRUGS IN CLINICAL STAGE
TABLE 29 HUMAN MICROBIOME DRUGS MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 30 NORTH AMERICA: HUMAN MICROBIOME DRUGS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 31 ASIA PACIFIC: HUMAN MICROBIOME DRUGS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 32 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 33 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 34 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 35 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 37 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 38 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 39 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 40 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 41 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 42 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 43 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 44 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 45 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 46 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 47 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 48 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 49 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 50 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 51 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 52 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 53 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 54 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 55 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 56 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 58 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 59 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 60 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 61 HUMAN MICROBIOME DIAGNOSTICS MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 62 NORTH AMERICA: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 63 EUROPE: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 64 ASIA PACIFIC: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 65 LATIN AMERICA: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 66 MIDDLE EAST: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 67 GCC COUNTRIES: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 68 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 69 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY REGION, 2023–2031 (USD MILLION)
TABLE 70 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 71 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 72 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY REGION, 2023–2031 (USD MILLION)
TABLE 73 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 74 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 75 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 76 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 77 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY REGION, 2023–2031 (USD MILLION)
TABLE 78 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 79 HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY REGION, 2023–2031 (USD MILLION)
TABLE 80 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 81 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 83 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 84 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY REGION, 2023–2031 (USD MILLION)
TABLE 85 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 86 HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 87 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES
TABLE 88 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2031 (USD MILLION)
TABLE 89 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 90 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 91 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2031 (USD MILLION)
TABLE 92 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 93 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 94 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 95 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 96 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2031 (USD MILLION)
TABLE 97 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 98 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2031 (USD MILLION)
TABLE 99 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 100 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 101 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 102 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 103 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2031 (USD MILLION)
TABLE 104 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 105 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2031 (USD MILLION)
TABLE 106 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 107 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 108 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 109 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 110 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2031 (USD MILLION)
TABLE 111 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 112 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 113 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2031 (USD MILLION)
TABLE 114 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 115 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 116 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 117 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 118 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2031 (USD MILLION)
TABLE 119 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 120 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2031 (USD MILLION)
TABLE 121 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 122 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 123 HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE, 2023–2031 (USD MILLION)
TABLE 124 HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 125 HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 126 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 127 EUROPE: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 128 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 129 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 130 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 131 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 132 HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2031 (USD MILLION)
TABLE 133 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 134 EUROPE: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 135 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 136 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 137 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2031 (USD MILLION)
TABLE 138 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 139 HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION)
TABLE 140 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 141 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 142 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 143 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 144 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION)
TABLE 145 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 146 HUMAN MICROBIOME MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 147 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 148 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 149 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 150 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 151 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 152 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 153 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 154 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
TABLE 155 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 156 US: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 157 US: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 158 US: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 159 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 160 US: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 161 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 162 CANADA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 163 CANADA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 164 CANADA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 165 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 166 CANADA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 167 EUROPE: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 168 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 169 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 170 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 171 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 172 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 173 EUROPE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 174 EUROPE: KEY MACROECONOMIC INDICATORS
TABLE 175 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 176 GERMANY: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 177 GERMANY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 178 GERMANY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 179 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 180 GERMANY: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 181 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 182 UK: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 183 UK: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 184 UK: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 185 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 186 UK: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 187 HUMAN MICROBIOME STARTUPS IN FRANCE
TABLE 188 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 189 FRANCE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 190 FRANCE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 191 FRANCE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 192 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 193 FRANCE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 194 ITALY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 195 ITALY: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 196 ITALY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 197 ITALY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 198 ITALY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 199 ITALY: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 200 SPAIN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 201 SPAIN: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 202 SPAIN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 203 SPAIN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 204 SPAIN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 205 SPAIN: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 206 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 207 REST OF EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 208 REST OF EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 209 REST OF EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 210 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 211 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 212 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 213 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 214 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 215 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 216 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 217 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 218 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 219 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 220 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 221 CHINA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 222 CHINA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 223 CHINA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 224 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 225 CHINA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 226 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 227 JAPAN: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 228 JAPAN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 229 JAPAN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 230 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 231 JAPAN: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 232 HUMAN MICROBIOME DIAGNOSTICS COMPANIES IN INDIA
TABLE 233 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 234 INDIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 235 INDIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 236 INDIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 237 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 238 INDIA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 239 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 240 SOUTH KOREA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 241 SOUTH KOREA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 242 SOUTH KOREA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 243 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 244 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 245 AUSTRALIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 246 AUSTRALIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 247 AUSTRALIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 248 AUSTRALIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 249 AUSTRALIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 250 AUSTRALIA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 251 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 252 REST OF ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 253 REST OF ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 254 REST OF ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 255 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 256 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 257 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 258 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 259 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 260 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 261 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 262 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 263 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 264 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
TABLE 265 BRAZIL: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 266 BRAZIL: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 267 BRAZIL: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 268 BRAZIL: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 269 BRAZIL: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 270 BRAZIL: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 271 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 272 REST OF LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 273 REST OF LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 274 REST OF LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 275 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 276 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 277 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 278 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 279 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 280 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 281 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 282 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 283 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 284 MIDDLE EAST: KEY MACROECONOMIC INDICATORS
TABLE 285 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 286 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 287 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 288 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 289 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 290 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 291 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 292 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 293 SAUDI ARABIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 294 SAUDI ARABIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 295 SAUDI ARABIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 296 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 297 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 298 UAE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 299 UAE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 300 UAE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 301 UAE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 302 UAE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 303 UAE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 304 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 305 REST OF GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 306 REST OF GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 307 REST OF GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 308 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 309 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 310 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 311 REST OF MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 312 REST OF MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 313 REST OF MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 314 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 315 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 316 AFRICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 317 AFRICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 318 AFRICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 319 AFRICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 320 AFRICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 321 AFRICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 322 AFRICA: KEY MACROECONOMIC INDICATORS
TABLE 323 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET, JANUARY 2022–JULY 2025
TABLE 324 HUMAN MICROBIOME MARKET: DEGREE OF COMPETITION, 2024
TABLE 325 HUMAN MICROBIOME MARKET: REGION FOOTPRINT
TABLE 326 HUMAN MICROBIOME MARKET: DRUG & SUPPLEMENT FOOTPRINT
TABLE 327 HUMAN MICROBIOME MARKET: TYPE FOOTPRINT
TABLE 328 HUMAN MICROBIOME MARKET: DISEASE FOOTPRINT
TABLE 329 HUMAN MICROBIOME MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 330 HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
TABLE 331 HUMAN MICROBIOME MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 332 HUMAN MICROBIOME MARKET: DEALS, JANUARY 2022–JULY 2025
TABLE 333 HUMAN MICROBIOME MARKET: EXPANSIONS, JANUARY 2022–JULY 2025
TABLE 334 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW
TABLE 335 INTERNATIONAL FLAVORS & FRAGRANCES INC.: PRODUCTS OFFERED
TABLE 336 INTERNATIONAL FLAVORS & FRAGRANCES INC.: DEALS, JANUARY 2022–JULY 2025
TABLE 337 INTERNATIONAL FLAVORS & FRAGRANCES INC.: EXPANSIONS, JANUARY 2022–JULY 2025
TABLE 338 SEED HEALTH, INC.: COMPANY OVERVIEW
TABLE 339 SEED HEALTH, INC.: PRODUCTS OFFERED
TABLE 340 SEED HEALTH, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 341 SEED HEALTH, INC.: DEALS, JANUARY 2022–JULY 2025
TABLE 342 SEED HEALTH, INC.: EXPANSIONS, JANUARY 2022?JULY 2025
TABLE 343 SERES THERAPEUTICS: COMPANY OVERVIEW
TABLE 344 SERES THERAPEUTICS: PRODUCTS OFFERED
TABLE 345 SERES THERAPEUTICS: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 346 SERES THERAPEUTICS: DEALS, JANUARY 2022–JULY 2025
TABLE 347 FERRING B.V.: COMPANY OVERVIEW
TABLE 348 FERRING B.V.: PRODUCTS OFFERED
TABLE 349 FERRING B.V.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 1 HUMAN MICROBIOME MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
TABLE 3 HUMAN MICROBIOME MARKET: RISK ANALYSIS
TABLE 4 HUMAN MICROBIOME MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 5 INDUSTRY COLLABORATIONS IN HUMAN MICROBIOME MARKET, 2022–2024
TABLE 6 LIST OF STARTUPS/SMES IN HUMAN MICROBIOME MARKET
TABLE 7 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)
TABLE 8 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2022–2024 (USD)
TABLE 9 HUMAN MICROBIOME MARKET: MAJOR INVESTMENT AND FUNDING, 2022–2024
TABLE 10 HUMAN MICROBIOME MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023–2024
TABLE 11 HUMAN MICROBIOME MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
TABLE 12 TARIFF DATA FOR HS CODE 3002.90
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 REGULATORY LANDSCAPE OF LIVE BIOTHERAPEUTIC PRODUCTS
TABLE 18 HUMAN MICROBIOME MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
TABLE 20 KEY BUYING CRITERIA, BY END USER
TABLE 21 KEY PLAYERS IMPLEMENTING AI IN HUMAN MICROBIOME
TABLE 22 COMPANIES LEVERAGING AI IN HUMAN MICROBIOME MARKET
TABLE 23 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 24 KEY PRODUCT-RELATED TARIFF: PHARMACEUTICAL PRODUCTS, MISCELLANEOUS EDIBLE PREPARATIONS, AND PRODUCTS OF ANIMAL ORIGIN
TABLE 25 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES
TABLE 26 HUMAN MICROBIOME SUPPLEMENTS POSITIONED AS GLP-1 SUPPORT
TABLE 27 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 28 HUMAN MICROBIOME DRUGS IN CLINICAL STAGE
TABLE 29 HUMAN MICROBIOME DRUGS MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 30 NORTH AMERICA: HUMAN MICROBIOME DRUGS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 31 ASIA PACIFIC: HUMAN MICROBIOME DRUGS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 32 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 33 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 34 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 35 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 37 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 38 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 39 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 40 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 41 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 42 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 43 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 44 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 45 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 46 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 47 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 48 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 49 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 50 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 51 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 52 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 53 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 54 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 55 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 56 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 58 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 59 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 60 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 61 HUMAN MICROBIOME DIAGNOSTICS MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 62 NORTH AMERICA: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 63 EUROPE: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 64 ASIA PACIFIC: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 65 LATIN AMERICA: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 66 MIDDLE EAST: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 67 GCC COUNTRIES: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 68 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 69 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY REGION, 2023–2031 (USD MILLION)
TABLE 70 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 71 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 72 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY REGION, 2023–2031 (USD MILLION)
TABLE 73 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 74 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 75 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 76 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 77 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY REGION, 2023–2031 (USD MILLION)
TABLE 78 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 79 HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY REGION, 2023–2031 (USD MILLION)
TABLE 80 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 81 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 83 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 84 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY REGION, 2023–2031 (USD MILLION)
TABLE 85 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 86 HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 87 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES
TABLE 88 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2031 (USD MILLION)
TABLE 89 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 90 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 91 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2031 (USD MILLION)
TABLE 92 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 93 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 94 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 95 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 96 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2031 (USD MILLION)
TABLE 97 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 98 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2031 (USD MILLION)
TABLE 99 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 100 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 101 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 102 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 103 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2031 (USD MILLION)
TABLE 104 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 105 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2031 (USD MILLION)
TABLE 106 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 107 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 108 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 109 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 110 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2031 (USD MILLION)
TABLE 111 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 112 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 113 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2031 (USD MILLION)
TABLE 114 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 115 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 116 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 117 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 118 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2031 (USD MILLION)
TABLE 119 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 120 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2031 (USD MILLION)
TABLE 121 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 122 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 123 HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE, 2023–2031 (USD MILLION)
TABLE 124 HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 125 HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 126 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 127 EUROPE: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 128 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 129 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 130 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 131 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 132 HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2031 (USD MILLION)
TABLE 133 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 134 EUROPE: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 135 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 136 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 137 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2031 (USD MILLION)
TABLE 138 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 139 HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION)
TABLE 140 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 141 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 142 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 143 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 144 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION)
TABLE 145 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 146 HUMAN MICROBIOME MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 147 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 148 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 149 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 150 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 151 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 152 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 153 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 154 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
TABLE 155 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 156 US: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 157 US: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 158 US: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 159 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 160 US: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 161 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 162 CANADA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 163 CANADA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 164 CANADA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 165 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 166 CANADA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 167 EUROPE: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 168 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 169 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 170 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 171 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 172 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 173 EUROPE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 174 EUROPE: KEY MACROECONOMIC INDICATORS
TABLE 175 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 176 GERMANY: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 177 GERMANY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 178 GERMANY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 179 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 180 GERMANY: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 181 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 182 UK: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 183 UK: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 184 UK: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 185 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 186 UK: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 187 HUMAN MICROBIOME STARTUPS IN FRANCE
TABLE 188 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 189 FRANCE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 190 FRANCE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 191 FRANCE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 192 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 193 FRANCE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 194 ITALY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 195 ITALY: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 196 ITALY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 197 ITALY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 198 ITALY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 199 ITALY: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 200 SPAIN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 201 SPAIN: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 202 SPAIN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 203 SPAIN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 204 SPAIN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 205 SPAIN: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 206 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 207 REST OF EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 208 REST OF EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 209 REST OF EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 210 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 211 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 212 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 213 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 214 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 215 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 216 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 217 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 218 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 219 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 220 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 221 CHINA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 222 CHINA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 223 CHINA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 224 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 225 CHINA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 226 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 227 JAPAN: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 228 JAPAN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 229 JAPAN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 230 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 231 JAPAN: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 232 HUMAN MICROBIOME DIAGNOSTICS COMPANIES IN INDIA
TABLE 233 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 234 INDIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 235 INDIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 236 INDIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 237 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 238 INDIA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 239 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 240 SOUTH KOREA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 241 SOUTH KOREA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 242 SOUTH KOREA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 243 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 244 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 245 AUSTRALIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 246 AUSTRALIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 247 AUSTRALIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 248 AUSTRALIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 249 AUSTRALIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 250 AUSTRALIA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 251 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 252 REST OF ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 253 REST OF ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 254 REST OF ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 255 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 256 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 257 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 258 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 259 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 260 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 261 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 262 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 263 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 264 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
TABLE 265 BRAZIL: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 266 BRAZIL: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 267 BRAZIL: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 268 BRAZIL: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 269 BRAZIL: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 270 BRAZIL: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 271 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 272 REST OF LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 273 REST OF LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 274 REST OF LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 275 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 276 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 277 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 278 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 279 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 280 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 281 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 282 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 283 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 284 MIDDLE EAST: KEY MACROECONOMIC INDICATORS
TABLE 285 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 286 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 287 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 288 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 289 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 290 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 291 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 292 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 293 SAUDI ARABIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 294 SAUDI ARABIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 295 SAUDI ARABIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 296 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 297 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 298 UAE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 299 UAE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 300 UAE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 301 UAE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 302 UAE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 303 UAE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 304 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 305 REST OF GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 306 REST OF GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 307 REST OF GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 308 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 309 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 310 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 311 REST OF MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 312 REST OF MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 313 REST OF MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 314 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 315 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 316 AFRICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 317 AFRICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 318 AFRICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 319 AFRICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 320 AFRICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 321 AFRICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 322 AFRICA: KEY MACROECONOMIC INDICATORS
TABLE 323 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET, JANUARY 2022–JULY 2025
TABLE 324 HUMAN MICROBIOME MARKET: DEGREE OF COMPETITION, 2024
TABLE 325 HUMAN MICROBIOME MARKET: REGION FOOTPRINT
TABLE 326 HUMAN MICROBIOME MARKET: DRUG & SUPPLEMENT FOOTPRINT
TABLE 327 HUMAN MICROBIOME MARKET: TYPE FOOTPRINT
TABLE 328 HUMAN MICROBIOME MARKET: DISEASE FOOTPRINT
TABLE 329 HUMAN MICROBIOME MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 330 HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
TABLE 331 HUMAN MICROBIOME MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 332 HUMAN MICROBIOME MARKET: DEALS, JANUARY 2022–JULY 2025
TABLE 333 HUMAN MICROBIOME MARKET: EXPANSIONS, JANUARY 2022–JULY 2025
TABLE 334 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW
TABLE 335 INTERNATIONAL FLAVORS & FRAGRANCES INC.: PRODUCTS OFFERED
TABLE 336 INTERNATIONAL FLAVORS & FRAGRANCES INC.: DEALS, JANUARY 2022–JULY 2025
TABLE 337 INTERNATIONAL FLAVORS & FRAGRANCES INC.: EXPANSIONS, JANUARY 2022–JULY 2025
TABLE 338 SEED HEALTH, INC.: COMPANY OVERVIEW
TABLE 339 SEED HEALTH, INC.: PRODUCTS OFFERED
TABLE 340 SEED HEALTH, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 341 SEED HEALTH, INC.: DEALS, JANUARY 2022–JULY 2025
TABLE 342 SEED HEALTH, INC.: EXPANSIONS, JANUARY 2022?JULY 2025
TABLE 343 SERES THERAPEUTICS: COMPANY OVERVIEW
TABLE 344 SERES THERAPEUTICS: PRODUCTS OFFERED
TABLE 345 SERES THERAPEUTICS: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 346 SERES THERAPEUTICS: DEALS, JANUARY 2022–JULY 2025
TABLE 347 FERRING B.V.: COMPANY OVERVIEW
TABLE 348 FERRING B.V.: PRODUCTS OFFERED
TABLE 349 FERRING B.V.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
The human microbiome market for diabetes is expected to be active from 2022 onwards with North America estimated to grow at a highest CAGR of XX% from 2022 to 2023. This geographic segment is poised to reach $XX million by 2023 from $XX million in 2022.
Several leading players in the human microbiome market for diabetes incl ude Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Merck (U.S.), and Enterome Bioscience (France).
The therapeutic segment is expected to dominate the human microbiome applications market from 2019 onwards and is expected to grow at a CAGR of XX% from 2019 to 2023, to reach $XX million by 2023. This segment is estimated to be the fastest-growing segment and is expected to lead the human microbiome application market by 2019. This is mainly attributed to the identification of new and specific bacterial macromolecules as potential therapeutic targets and the need for reliable, precise, and quicker detection of chronic lifestyle diseases and various other dis orders.
The, diagnostic segment is expected to enter the market in 2021 and estimated to grow at a CAGR of XX% from 2021 to 2023, to reach $XX million by 2023. However, limited awareness about microbiome-based applications and stringent regulatory policies are restricting the growth of this market.
Probiotics segment is expected to dominate the global human microbiome market in 2019 and estimated to grow at a CAGR of XX% from 2019 to 2023, to reach $XX million by 2023. The prebiotics segment is expected to be the fastest-growing, projected to grow at a CAGR of XX% from 2019 to reach $XX million by 2023. Several leading market players are focusing on increasing their market share in the probiotics and prebiotics along with drugs, through various organic and inorganic growth strategies.
